Key Takeaways Medtronic secured FDA approval for its Altaviva implantable tibial neuromodulation device. MDT's device treats urge urinary incontinence through a minimally invasive ankle implant. MDT's Altaviva features a 15-year battery life, quick recharging, and MRI compatibility. Medtronic plc (MDT) recently received Food and Drug Administration (“FDA”) approval for the minimally invasive implantable tibial neuromodulation (ITNM) Altaviva device. The therapy is inserted near the ankle and designed to tre ...